7-11 boulevard Haussmann
Paris 75009
France
33 1 53 83 09 63
https://www.abivax.com
Sector(s):
Industry:
Full-time employees: 61
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Philippe Pouletty M.D., Ph.D. | Founder & Director | N/A | N/A | 1958 |
Mr. Didier Blondel | EVP, CFO & Board Secretary | N/A | N/A | 1964 |
Mr. Didier Scherrer Ph.D. | Chief Scientific Officer | N/A | N/A | 1970 |
Mr. Patrick Malloy | Senior Vice President of Investor Relations | N/A | N/A | N/A |
Ms. Ida Hatoum | Chief People Officer | N/A | N/A | 1975 |
Mr. Pierre Courteille M.B.A. | Chief Business Officer | N/A | N/A | 1969 |
Mr. Jerome Denis Ph.D. | Executive Vice President of Process Development & Manufacturing | N/A | N/A | N/A |
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
ABIVAX Société Anonyme’s ISS governance QualityScore as of 1 July 2024 is 10. The pillar scores are Audit: 10; Board: 9; Shareholder rights: 7; Compensation: 10.